Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a variety of clinical manifestations that can affect various organs and systems of the body. In SLE, the immune system begins to attack its own cells and tissues, which leads to inflammation and damage. The disease can manifest itself in the form of skin rashes, arthritis, damage to the kidneys, lungs, heart and other organs. SLE has a variable course, with periods of exacerbations and remissions, which makes diagnosis and treatment especially difficult. The causes of the disease remain not fully understood, but a combination of genetic predisposition, immunological changes and external factors is assumed.
History of the disease and interesting historical facts
Systemic lupus erythematosus was first described in the early 19th century, but systematic study of the disease began much later. In 1851, French dermatologist Pierre-René Suart first mentioned specific skin manifestations associated with lupus. However, it was not until 1895 that German physician Friedrich Klauff defined SLE as a systemic disease affecting not only the skin but also other organs. Since then, doctors have begun to study its manifestations and pathogenesis in more depth. An interesting fact is that the name "lupus" comes from the Latin word "lupus", meaning "wolf", since the skin of patients sometimes has a characteristic appearance reminiscent of the bites of this animal. In 1948, it was discovered that the blood of patients with SLE contains antinuclear antibodies, which helped in diagnosing the disease.
Epidemiology
Systemic lupus erythematosus is a fairly common disease. According to various studies, the prevalence of SLE ranges from 20 to 150 cases per 100,000 people, depending on the region. A higher incidence rate is observed in women, especially those aged 15 to 44 years. The incidence rate between women and men is approximately 9:1. Due to genetic predisposition, SLE is more common in people with certain ethnic characteristics, such as African Americans, Hispanics, and Native Americans, in whom the incidence can reach 10-15 cases per 100,000 people.
Genetic predisposition to this disease
Genetic predisposition has been shown to play an important role in the development of systemic lupus erythematosus. Studies show that close relatives of patients with SLE have a significantly higher risk of developing the disease. There are certain genes associated with increased risk, including genes responsible for the functioning of the immune system, such as the major histocompatibility complex (HLA) class III genes. The most studied of these include HLA-DR2, HLA-DR3, and HLA-DQ. Mutations in other genes, such as the TREX1 gene, have also been associated with the development of lupus. In addition, the scientific literature increasingly attaches importance to polygenic influences, where the interaction of several genes can predispose to the disease.
Risk factors for the development of this disease
There are several known risk factors that contribute to the development of systemic lupus erythematosus:
- Gender: Women are 9 times more likely to suffer from SLE than men.
- Age: The disease most often manifests itself in adolescence and reproductive age, from 15 to 44 years.
- Ethnicity: Higher incidence is seen in African Americans, Hispanics, and Native Americans.
- Environmental exposures: Exposure to certain chemicals (e.g., drugs containing hydroxychloroquine, etc.) is associated with increased risk.
- Infections: Some viral infections, such as Epstein-Barr, can trigger a flare-up of the disease.
- Hormonal factors: A link to changes in hormone levels, particularly estrogen, has been established, which may explain the prevalence of the disease in women.
Diagnosis of this disease
Diagnosis of systemic lupus erythematosus is based on a combination of clinical manifestations and laboratory tests. The main symptoms of the disease may include:
- Skin rashes, especially on the face and cheek area (“butterfly rash”).
- Pain and swelling in the joints (arthritis).
- Kidney damage (leptospirosis).
- Problems with the central nervous system, including headaches and psychosis.
- Pathological changes in the lungs and heart (pleurisy, pericarditis).
Laboratory tests include antinuclear antibodies (ANA), specific antibodies (eg, anti-histone antibodies and anti-mitochondrial antibodies), and antibody complex tests. Radiologic tests may detect changes in organ systems, such as chest X-rays to evaluate pleurisy and other changes. Differential diagnoses include rheumatoid arthritis, dermatomyositis, and other autoimmune diseases.
Treatment
Treatment of systemic lupus erythematosus includes both general measures and specific drug therapy. The main approach is to control symptoms and prevent exacerbations. Pharmacological treatment may include:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce joint pain and inflammation symptoms.
- Corticosteroids to control severe exacerbations.
- Immunosuppressant drugs such as azathioprine and mycophenolate mofetil to reduce the activity of the immune system.
- Biologics, such as rituximab and belimumab, target specific disease mechanisms.
Surgical treatment may be indicated in cases of severe organ damage, such as the need for a kidney transplant. The use of comprehensive treatment programs, including physical therapy and psychosocial support, is also recommended.
List of medications used to treat this disease
- Naproxen
- Ibuprofen
- Prednisolone
- Azathioprine
- Mycophenolate mofetil
- Rituximab
- Belimumab
Disease monitoring
Monitoring the patient's condition with systemic lupus erythematosus is a key aspect of treatment. Monitoring steps should include regular visits to the doctor, periodic antibody testing, and laboratory tests to assess kidney and liver function. The prognosis of the disease varies depending on the clinical manifestations and individual characteristics of the disease course. Complications may include kidney failure, cardiovascular disease, and osteoporosis.
Age-related features of the disease
Systemic lupus erythematosus may present differently in different age groups. Young women are more likely to have acute manifestations, while in older people the disease may have a milder and more gradual course. In children, SLE may present aggressively, including nephritis and damage to the nervous system, which requires early and active diagnosis and therapy.
Questions and Answers
- How does systemic lupus erythematosus affect a patient's quality of life? SLE can significantly reduce quality of life, leading to chronic pain, fatigue and functional limitations.
- Is it possible to completely cure systemic lupus erythematosus? Currently, SLE is a chronic disease with no cure, but symptoms can be effectively controlled.
- How often should I have follow-up tests for SLE? It is recommended to conduct control tests at least once every three months, and more often during periods of exacerbation.
- Can stress trigger an exacerbation of SLE? Yes, stress can be a trigger for exacerbation of the disease in predisposed patients.
- What to do if SLE symptoms worsen? If symptoms worsen, you should consult a doctor to adjust therapy and monitor your condition.
